These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 26086136)

  • 41. Mononuclear phagocytes from patients with active systemic lupus erythematosus down-regulate the specific in vitro reactivity of autologous lymphocytes to double-stranded DNA.
    Weill BJ; Renoux ML
    Clin Exp Immunol; 1988 Apr; 72(1):43-9. PubMed ID: 3293851
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Peripheral B cell abnormalities and disease activity in systemic lupus erythematosus.
    Hostmann A; Jacobi AM; Mei H; Hiepe F; Dörner T
    Lupus; 2008 Dec; 17(12):1064-9. PubMed ID: 19029273
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A subset of systemic sclerosis but not of systemic lupus erythematosus is defined by isolated anti-Ku autoantibodies.
    Cavazzana I; Fredi M; Taraborelli M; Quinzanini M; Tincani A; Franceschini F
    Clin Exp Rheumatol; 2013; 31(2 Suppl 76):118-21. PubMed ID: 23910615
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Binding characteristics of SLE anti-DNA autoantibodies to Catecholestrogen-modified DNA.
    Khan WA
    Scand J Immunol; 2006 Dec; 64(6):677-83. PubMed ID: 17083625
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia.
    Kuwana M; Okazaki Y; Kajihara M; Kaburaki J; Miyazaki H; Kawakami Y; Ikeda Y
    Arthritis Rheum; 2002 Aug; 46(8):2148-59. PubMed ID: 12209520
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome.
    Delgado Alves J; Kumar S; Isenberg DA
    Rheumatology (Oxford); 2003 Jul; 42(7):893-9. PubMed ID: 12730551
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Origin of anti-DNA autoantibodies in SLE.
    Winkler TH; Kalden JR
    Lupus; 1994 Apr; 3(2):75-6. PubMed ID: 7920617
    [No Abstract]   [Full Text] [Related]  

  • 48. Anti-C1q autoantibodies amplify pathogenic complement activation in systemic lupus erythematosus.
    Holers VM
    J Clin Invest; 2004 Sep; 114(5):616-9. PubMed ID: 15343378
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Do naturally occurring autoantibodies participate in the constitution of the pathological B-cell repertoire in systemic lupus erythematosus?
    Gilbert D; Brard F; Jovelin F; Tron F
    J Autoimmun; 1996 Apr; 9(2):247-57. PubMed ID: 8738970
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-prolactin autoantibodies in pregnant women with systemic lupus erythematosus: maternal and fetal outcome.
    Leaños-Miranda A; Cárdenas-Mondragón G; Ulloa-Aguirre A; Isordia-Salas I; Parra A; Ramírez-Peredo J
    Lupus; 2007; 16(5):342-9. PubMed ID: 17576736
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antiribonuclease H2 antibodies are an immune biomarker for systemic lupus erythematosus.
    Nozawa K; Doe K; Uomori K; Sekigawa I; Takasaki Y; Yamaji K; Tamura N
    Autoimmunity; 2017 Jun; 50(4):241-246. PubMed ID: 28553742
    [TBL] [Abstract][Full Text] [Related]  

  • 52. IgG autoantibodies to complement C1q in pediatric-onset systemic lupus erythematosus.
    Ravelli A; Wisnieski JJ; Ramenghi B; Ballardini G; Zonta L; Martini A
    Clin Exp Rheumatol; 1997; 15(2):215-9. PubMed ID: 9196878
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of anti-prolactin autoantibodies in systemic lupus erythematosus.
    Blanco-Favela F; Chavez-Rueda K; Leaños-Miranda A
    Lupus; 2001; 10(10):757-61. PubMed ID: 11721703
    [TBL] [Abstract][Full Text] [Related]  

  • 54. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection.
    McKinney EF; Lee JC; Jayne DR; Lyons PA; Smith KG
    Nature; 2015 Jul; 523(7562):612-6. PubMed ID: 26123020
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Ro60 autoantigen binds endogenous retroelements and regulates inflammatory gene expression.
    Hung T; Pratt GA; Sundararaman B; Townsend MJ; Chaivorapol C; Bhangale T; Graham RR; Ortmann W; Criswell LA; Yeo GW; Behrens TW
    Science; 2015 Oct; 350(6259):455-9. PubMed ID: 26382853
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activation of cyclic GMP-AMP synthase by self-DNA causes autoimmune diseases.
    Gao D; Li T; Li XD; Chen X; Li QZ; Wight-Carter M; Chen ZJ
    Proc Natl Acad Sci U S A; 2015 Oct; 112(42):E5699-705. PubMed ID: 26371324
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CD32a antibodies induce thrombocytopenia and type II hypersensitivity reactions in FCGR2A mice.
    Meyer T; Robles-Carrillo L; Davila M; Brodie M; Desai H; Rivera-Amaya M; Francis JL; Amirkhosravi A
    Blood; 2015 Nov; 126(19):2230-8. PubMed ID: 26396093
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The type I interferons: Basic concepts and clinical relevance in immune-mediated inflammatory diseases.
    López de Padilla CM; Niewold TB
    Gene; 2016 Jan; 576(1 Pt 1):14-21. PubMed ID: 26410416
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Defects in Germinal Center Selection in SLE.
    Woods M; Zou YR; Davidson A
    Front Immunol; 2015; 6():425. PubMed ID: 26322049
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
    Merrill JT; van Vollenhoven RF; Buyon JP; Furie RA; Stohl W; Morgan-Cox M; Dickson C; Anderson PW; Lee C; Berclaz PY; Dörner T
    Ann Rheum Dis; 2016 Feb; 75(2):332-40. PubMed ID: 26293163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.